Igor Filipčić

Igor Filipčić

Auto-generated profile, based on publicly available information

Igor Filipčić

Josip Juraj Strossmayer University of Osijek

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
IFIgor Filipčić
Igor Filipčić
IFIvona Šimunović Filipčić
Ivona Šimunović Filipčić
ŽMŽeljko Milovac
Željko Milovac
SSStrahimir Sučić
Strahimir Sučić
TGTomislav Gajšak
Tomislav Gajšak
MHMarkus Heilig
Markus Heilig

1 November 2018 in Journal of Psychosomatic Research
Verified
Journal Article
Closed access
IFIgor Filipčić
Igor Filipčić
IFIvona Šimunović Filipčić
Ivona Šimunović Filipčić
VGVladimir Grošić
Vladimir Grošić
IBIvana Bakija
Ivana Bakija
DŠDaniela Šago
Daniela Šago
Norman SaratoriusNorman Saratorius
Norman Saratorius

21 March 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
MPMatea Nikolac Perkovic
Matea Nikolac Perkovic
FBFran Borovecki
Fran Borovecki
IFIgor Filipcic
Igor Filipcic
BVBarbara Vuic
Barbara Vuic
TMTina Miloš
Tina Miloš
Nela PivacNela Pivac
Nela Pivac
In the last decade, increasing evidence has emerged linking alterations in the brain-derived neurotrophic factor (BDNF) expression with the development of Alzheimer’s disease (AD). Because of the important role of BDNF in cognition and its association with AD pathogenesis, the aim of this study was to evaluate the potential difference in plasma BDNF concentrations between subjects with mild cognitive impairment (MCI; N = 209) and AD patients (N = 295) and to determine the possible association between BDNF plasma levels and the degree of cognitive decline in these individuals. The results showed a significantly higher (p < 0.001) concentration of plasma BDNF in subjects with AD (1.16; 0.13–21.34) compared with individuals with MCI (0.68; 0.02–19.14). The results of the present study additionally indicated a negative correlation between cognitive functions and BDNF plasma concentrations, suggesting higher BDNF levels in subjects with more pronounced cognitive decline. The correlation analysis revealed a significant negative correlation between BDNF plasma levels and both Mini-Mental State Examination (p < 0.001) and Clock Drawing test (p < 0.001) scores. In conclusion, the results of our study point towards elevated plasma BDNF levels in AD patients compared with MCI subjects, which may be due to the body’s attempt to counteract the early and middle stages of neurodegeneration.

6 July 2020 in Current Opinion in Psychiatry
Verified
Journal Article
Closed access
IFIvona Šimunović Filipčić
Ivona Šimunović Filipčić
ŽBŽarko Bajić
Žarko Bajić
IFIgor Filipčić
Igor Filipčić
Purpose of review: Despite of the heightened risks and burdens of physical comorbidities across the entire spectrum of mental disorders, relatively little is known about physical multimorbidity in this population. The aim of this narrative review is to present recent data regarding the onset and accumulation of physical multimorbidity and to assess its impact on the onset, course, treatment, and outcomes of mental disorders. Recent findings: A substantial body of literature shows increased risk of physical multimorbidity among people with mental disorders. The disparity in physical multimorbidity occurs even before the diagnosis of mental disorder, and the younger age group appears to be at particular risk. Numerous patterns of association between mental disorders and medical disorders involving multiple organ systems have been identified. Physical multimorbidity affects people with mental disorders across their life spans, is associated with a wide range of unfavorable outcomes and presents significant clinical and public health concerns. Summary: To address physical health inequalities among people with mental disorders compared with the general population, we must focus on the physical health from the very first point of contact with a mental health service. Treatment of mental disorders must be customized to meet the needs of patients with different physical multimorbidity patterns. Future work is needed to clarify how physical multimorbidity influences mental disorder treatment outcomes.

20 October 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
SSSanja Strbe
Sanja Strbe
SGSlaven Gojkovic
Slaven Gojkovic
IKIvan Krezic
Ivan Krezic
HŽHelena Žižek
Helena Žižek
Hrvoje VranesHrvoje Vranes
Hrvoje Vranes
PSPredrag Sikiric
Predrag Sikiric
Due to endothelial impairment, high-dose lithium may produce an occlusive-like syndrome, comparable to permanent occlusion of major vessel-induced syndromes in rats; intracranial, portal, and caval hypertension, and aortal hypotension; multi-organ dysfunction syndrome; brain, heart, lung, liver, kidney, and gastrointestinal lesions; arterial and venous thrombosis; and tissue oxidative stress. Stable gastric pentadecapeptide BPC 157 may be a means of therapy via activating loops (bypassing vessel occlusion) and counteracting major occlusion syndromes. Recently, BPC 157 counteracted the lithium sulfate regimen in rats (500 mg/kg/day, ip, for 3 days, with assessment at 210 min after each administration of lithium) and its severe syndrome (muscular weakness and prostration, reduced muscle fibers, myocardial infarction, and edema of various brain areas). Subsequently, BPC 157 also counteracted the lithium-induced occlusive-like syndrome; rapidly counteracted brain swelling and intracranial (superior sagittal sinus) hypertension, portal hypertension, and aortal hypotension, which otherwise would persist; counteracted vessel failure; abrogated congestion of the inferior caval and superior mesenteric veins; reversed azygos vein failure; and mitigated thrombosis (superior mesenteric vein and artery), congestion of the stomach, and major hemorrhagic lesions. Both regimens of BPC 157 administration also counteracted the previously described muscular weakness and prostration (as shown in microscopic and ECG recordings), myocardial congestion and infarction, in addition to edema and lesions in various brain areas; marked dilatation and central venous congestion in the liver; large areas of congestion and hemorrhage in the lung; and degeneration of proximal and distal tubules with cytoplasmic vacuolization in the kidney, attenuating oxidative stress. Thus, BPC 157 therapy overwhelmed high-dose lithium intoxication in rats.

1 June 2017 in European Psychiatry
Verified
Journal Article
Closed access
IFI. Filipcic
I. Filipcic
IFIvona Šimunović Filipčić
Ivona Šimunović Filipčić
EIE. Ivezic
E. Ivezic
KMK. Matic
K. Matic
NVN. Tunjic Vukadinovic
N. Tunjic Vukadinovic
NSN. Sartorius
N. Sartorius
Background: Increased physical morbidity in patients with schizophrenia spectrum disorders (SSDs) is well documented. However, much less is known about the association between somatic comorbidities and psychosis treatment outcomes.Subjects and methods: This cross-sectional study, nested within the larger frame of a prospective cohort study, was done in 2016 at Psychiatric Hospital Sveti Ivan, Zagreb, Croatia. Data were collected on a consecutive sample of 301 patients diagnosed with schizophrenia spectrum disorders who achieved a stable therapeutic dosage. Key outcome was the number of psychiatric rehospitalizations since diagnosis of the primary psychiatric illness. Predictors were number of physical and psychiatric comorbidities. By robust regression, we controlled different clinical, sociodemographic, and lifestyle confounding factors.Results: The number of chronic somatic comorbidities was statistically significantly associated with a larger number of psychiatric rehospitalizations, even after the adjustment for number of psychiatric comorbidities and large number of other clinical, sociodemographic, and lifestyle variables.Conclusions: Chronic somatic comorbidities are associated with higher rates of psychiatric rehospitalization independently of psychiatric comorbidities and other clinical, sociodemographic, and lifestyle factors. Therefore, to treat psychosis effectively, it may be necessary to treat chronic somatic comorbidities promptly and adequately. Chronic somatic comorbidities should be considered equally important as the SSD, and should be brought to the forefront of psychiatric treatment and research with the SSD as one entity. The integrative approach should be the imperative in clinical practice.